View Financial HealthSanten Pharmaceutical 배당 및 자사주 매입배당 기준 점검 5/6Santen Pharmaceutical 수익으로 충분히 충당되는 현재 수익률 1.99% 보유한 배당금 지급 회사입니다.핵심 정보2.0%배당 수익률5.4%자사주 매입 수익률총 주주 수익률7.3%미래 배당 수익률2.5%배당 성장률4.5%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향41%최근 배당 및 자사주 매입 업데이트공시 • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.공시 • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.공시 • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.공시 • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.공시 • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.모든 업데이트 보기Recent updates공시 • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.공시 • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026공시 • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.공시 • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026공시 • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.공시 • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025공시 • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025공시 • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.공시 • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.공시 • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025공시 • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025공시 • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.공시 • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024공시 • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024공시 • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.공시 • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.공시 • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024공시 • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.공시 • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024공시 • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.공시 • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023공시 • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023공시 • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.공시 • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.공시 • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023공시 • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: SNPH.Y 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: SNPH.Y 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Santen Pharmaceutical 배당 수익률 vs 시장SNPH.Y의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SNPH.Y)2.0%시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (SNPH.Y) (최대 3년)2.5%주목할만한 배당금: SNPH.Y 의 배당금( 1.99% )은 US 시장에서 배당금 지급자의 하위 25%( 1.41% )보다 높습니다.고배당: SNPH.Y 의 배당금( 1.99% )은 US 시장에서 배당금 지급자의 상위 25%( 4.24% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적으로 낮은 지불 비율 ( 41.3% )로 SNPH.Y 의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 40.5% )로 SNPH.Y 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 14:23종가2026/05/22 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Santen Pharmaceutical Co., Ltd.는 18명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Atsushi SekiBarclaysKoichi MameganoBofA Global ResearchHidemaru YamaguchiCitigroup Inc15명의 분석가 더 보기
공시 • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.
공시 • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.
공시 • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.
공시 • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.
공시 • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.
공시 • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2026.
공시 • May 09Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 12, 2026Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 12, 2026
공시 • Jan 08RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ ®? Mini Ophthalmic Solution 0.1%RVL Pharmaceuticals Inc. and its affiliates announced Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ®? Mini Ophthalmic Solution 0.1% (generic name:oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq®? is the first and only FDA-approved prescription eye drop for acquired blepharoptOS (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil) at Day 14 after the start of treatment--in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward strengthening of the eyelid-lifting effect or rebound effect was observed. In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. Upneeq®? (oxymetazoline hydrochlorides ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis ("low-lying lids") in adults. The product was approved in the US by the FDA in July 2020. Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect blood pressure. Upneeq®? activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800.
공시 • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 05, 2026
공시 • Nov 07Santen Pharmaceutical Co., Ltd. Receives UK Approval for Ryjunea®? (Low-Dose Atropine 0.1 Mg/L) to Slow Progression of Childhood MyopiaSanten announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea®? (low-dose atropine 0.1 mg/ml), the first licensed treatment in the UK to slow the progression of myopia in children. The approval follows the European Commission authorisation and the first launch in Germany earlier this year, with additional launches in Europe to follow. Short-sightedness is rising fast among children in the UK, where many children now live with myopia, more than double the number from 50 years ago. Increased screen time, less outdoor activity, and intensive near work are putting a growing strain on young eyes. Globally, approximately one in three children and adolescents are expected to be affected by 2050. The first signs of myopia often appear in daily life: a child squinting to read the board, moving closer to the TV, or struggling to recognise faces at a distance. Myopia can affect learning, confidence, and participation in school and play. Early interventions are key to slowing progression and supporting children's eye health and wellbeing. Childhood myopia increases the risk of severe eye disease later in life. "A comprehensive approach, combining lifestyle habits, optical correction, and approved medical options, gives children the best chance to support healthy vision into adulthood." With over 135 years of experience in eye health, Santen is committed to advancing early intervention and collaboration in paediatric myopia, for happier lives and brighter futures. Ryjunea®? is a registered trademark of Santen Pharmaceutical Co., Ltd. Ryjunea®®? is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. It is backed by the Phase III STAR study, showing that Ryjunea®? significantly reduced the annual progression of myopia with an acceptable safety and tolerability profile. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child's routine. The product is licensed from Sydnexis Inc. to Santen's Switzerland-based affiliate, Santen SA, for registration and commercialisation across Europe, the Middle East, and Africa (EMEA). It has received market authorisation from the European Commission on June 2, and now from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on October 30.
공시 • Sep 01Santen Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 06, 2025
공시 • Jun 06Santen Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
공시 • May 15Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 19,800,000 shares, representing 5.8% for ¥35,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 19,800,000 of its common shares, representing 5.8% of its outstanding shares for ¥35,000 million. The program is aimed at enhancing shareholder returns and further improving capital efficiency. The plan will be valid up to November 5, 2025. As on November 5, 2025, the company had 341,423,368 shares outstanding and 632,186 shares in its treasury.
공시 • May 14Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.
공시 • Mar 06Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
공시 • Dec 03Santen Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 06, 2025
공시 • Nov 07Santen Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 5,000,000 shares, representing 1.44% for ¥10,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 of its common shares, representing 1.44% of its outstanding shares for ¥10,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to March 21, 2025. As on October 31, 2024, the company had 347,002,868 shares outstanding and 17,019,386 shares in its treasury.
공시 • Sep 04Santen Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
공시 • Jun 02Santen Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 06, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024
공시 • May 11Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024.
공시 • May 10+ 3 more updatesSanten Pharmaceutical Co., Ltd. (TSE:4536) announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan. The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.
공시 • Mar 02Santen Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024Santen Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 09, 2024
공시 • Feb 09Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. Revised Dividend guidance for the Fiscal Year Ending March 31, 2024. For the year, the company expects dividend of JPY 17.00 per share against previous guidance of JPY 16.00 per share.
공시 • Dec 02Santen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 08, 2024Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 08, 2024
공시 • Sep 21Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 compared to the previous guidance of revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27 provided earlier. On IFRS basis, the company expects revenue of ¥285,000 million, operating profit of ¥35,000 million, net profit for the year of ¥25,000 million and basic earnings per share of ¥68.34 compared to the previous guidance of revenue of ¥273,000 million, operating profit of ¥32,000 million, core net profit for the year of ¥22,400 million and basic core earnings per share of ¥61.24 provided earlier.
공시 • Aug 27Santen Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 07, 2023
공시 • May 31Santen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 03, 2023
공시 • May 12+ 2 more updatesSanten Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the End of Second Quarter and Full Year Ending March 31, 2024Santen Pharmaceutical Co., Ltd. announced year end dividend for the year ended March 31, 2023 of JPY 16.00 per share compared to JPY 16.00 per share a year ago. Start of Distribution of Dividends (Scheduled): June 28, 2023. The company provided dividend guidance for the end of second quarter and full year ending March 31, 2024. For the end of second quarter, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.For the year, the company expects to pay dividend of JPY 16.00 per share compared to JPY 16.00 per share a year ago.
공시 • Feb 08Santen Pharmaceutical Co., Ltd. Revises Consolidated and Core Earnings Guidance for the Year Ending March 31, 2023Santen Pharmaceutical Co., Ltd. revised consolidated and core earnings guidance for the year ending March 31, 2023. For the year on consolidated basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Operating loss of JPY 6,500 million compared to previous guidance operating profit of JPY 4,000 million. Net loss for the year of JPY 15,500 million compared to previous guidance of JPY 5,500 million. Basic loss per share of JPY 40.01 compared to previous guidance of JPY 14.20.For the year on core basis, the company revised revenue of JPY 272,000 million compared to previous guidance of JPY 280,000 million. Core operating profit of JPY 41,000 million compared to previous guidance JPY 45,500 million. Core Net profit for the year of JPY 30,800 million compared to previous guidance of JPY 34,100 million. Core Basic earnings per share of JPY 79.50 compared to previous guidance of JPY 88.04.
공시 • Dec 18Santen Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 07, 2023Santen Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 07, 2023
공시 • May 12Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023Santen Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2023.